| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.1 | 0.9 |
| Gross profit | 0.7 | 0.5 |
| Profit before tax | -6.5 | -1.0 |
| Net income | -1.3 | -3.9 |
| EPS (diluted, $ a share) | $-0.04 | $-0.19 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +20.4% |
|---|---|
| Gross margin | 61.7% |
10-Q filed with the SEC, NASDAQ: ELUT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Elutia Inc.: key numbers
- Share price
- $0.8229Close, Nov 16
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Elutia Inc.
All →Elutia Financial Results
Elutia Inc. reported financial results for the third quarter of 2026, highlighted by 20% year-over-year revenue growth in its cardiovascular business. The company announced it is on track for a Q4 2026 FDA submission for NXT-41x, its antibacterial envelope for plastic surgery, and believes it is fully funded through 2028 commercialization after receiving $26 million in non-equity capital.
- Term
- Q3 2026
“We are out to solve it, and will take the next step this quarter with the NXT-41x FDA submission. After adding $26 million without an equity offering, we believe we have the technology, the team, and the capital to advance NXT-41x toward anticipated clearance in the first half of 2027 and through the first full year of commercial launch in 2028. In doing so, we will help patients thrive without compromise.”
Dr. Randy Mills, Chief Executive Officer of Elutia